ENVOY MEDICAL INC
COCHNASDAQTrading Snapshot
- Day Range
- $0.74 – $0.76
- 52-Week Range
- $0.36 – $1.89
- Volume
- $3.05B
- Avg Volume
- $3.48B
- Shares Outstanding
- 76.9M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $241,000
- Last Q Revenue
- $51,000
- P/E Ratio
- —
- P/S Ratio
- 231.6x
- EPS (TTM)
- $-0.86
- Dividend Yield
- 3.36%
Why Investors Own COCH
- ✓High-growth profile — revenue up +19.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ENVOY MEDICAL INC
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Envoy Medical Expects To Submit Four Modules, Final Module Of PMA Application Targeted For Submission In Q2 2027
-SEC Filing
Envoy Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $51.000K Miss $80.000K Estimate
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 78.13 percent increase over losses of $(0.32) per share from the
LUCID CAPITAL MARKETS Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.
Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build.
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant
Envoy Medical Inc. (NASDAQ:COCH) on Tuesday said it surpassed the three-month milestone for all 56 patients enrolled in the company’s pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant. Envoy Medical Completes Three-Month Milestone In Acclaim Trial The update marks another important clinical trial milestone as the company continues to build momentum with the hearing industry. Read Also: EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant